Business
Oncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver
Oncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal C...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver\n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\n\n\n\n\n\nOncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver\nCanada NewsWire\nCALGARY, June 29, 2016\n\n\n\n\nCALGARY, June 29, 2016 /CNW/ - Oncolytics Biotech Inc. (\"Oncolytics\" or the \"Company\") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced that, following\n submission to the U.S. Food and Drug Administration (\"FDA\") for review, the Investigational New Drug Application containing the\n protocol titled \"Phase 2 study of REOLYSIN® (pelareorep) in combination with FOLFOX6, bevacizumab and pembrolizumab\n in female patients with KRAS-mutant colorectal cancer metastatic to the\n liver\" is now active.\n\n\n\"This study is intended to confirm the encouraging objective overall and\n liver metastases response rates in female patients that we saw in a\n sponsored randomized Phase II study conducted in Canada,\" said Dr. Brad\n Thompson, President and CEO of Oncolytics. \"We are adding a checkpoint\n inhibitor to the treatment regimen based on our evolving understanding\n of how REOLYSIN® upregulates immune responses and how the combination may make cancer\n cells more susceptible to attack by the immune system.\"\n\n\nThis is a multicenter, single arm safety and efficacy study of REOLYSIN® in combination with chemotherapy (FOLFOX6), beva...